TY - JOUR
T1 - Prevalence of pre-existing hearing loss among patients with drug-resistant tuberculosis in South Africa
AU - Hong, Hyejeong
AU - Dowdy, David W.
AU - Dooley, Kelly E.
AU - Francis, Howard W.
AU - Budhathoki, Chakra
AU - Han, Hae Ra
AU - Farley, Jason E.
N1 - Funding Information:
Research reported in this article was supported by the National Institute of Allergy and Infectious Disease Grant R01 AI104488 (awarded to J. Farley), the National Institute of Nursing Research Grant F31 NR016910 (awarded to H. Hong), Sigma Theta Tau International Global Nursing Research Grant, Sigma Theta Tau International/Association of Nurses in AIDS Care Grant, Global Korean Nursing Foundation Scientific Award, Dr. Scholl Foundation Dissertation Scholarship, and the Johns Hopkins Center for Global Health Established Field Placements Grant. The content is solely the responsibility of the authors and does not necessarily represent the official views of the aforementioned organizations/institutions.
Funding Information:
Research reported in this article was supported by the National Institute of Allergy and Infectious Disease Grant R01 AI104488 (awarded to J. Farley), the National Institute of Nursing Research Grant F31 NR016910 (awarded to H. Hong), Sigma Theta Tau International Global Nursing Research Grant, Sigma Theta Tau International/Association of Nurses in AIDS Care Grant, Global Korean Nursing Foundation Scientific Award, Dr. Scholl Foundation Dissertation Scholarship, and the Johns Hopkins Center for Global Health Established Field Placements Grant. The content is solely the responsibility of the authors and does not necessarily represent the official views of the aforemen-tioned organizations/institutions.
Publisher Copyright:
© 2020 American Speech-Language-Hearing Association.
PY - 2020/6
Y1 - 2020/6
N2 - Purpose: Hearing loss, resulting from aminoglycoside ototoxicity, is common among patients with drug-resistant tuberculosis (DR-TB). Those with pre-existing hearing loss are at particular risk of clinically important hearing loss with aminoglycoside-containing treatment than those with normal hearing at baseline. This study aimed to identify factors associated with pre-existing hearing loss among patients being treated for DR-TB in South Africa. Method: Cross-sectional analysis nested within a cluster-randomized trial data across 10 South African TB hospitals. Patients ≥ 13 years old received clinical and audiological evaluations before DR-TB treatment initiation. Results: Of 936 patients, average age was 35 years. One hundred forty-two (15%) reported pre-existing auditory symptoms. Of 482 patients tested by audiometry, 290 (60%) had pre-existing hearing loss. The prevalence of pre-existing hearing loss was highest among patients ≥ 50 years (adjusted prevalence ratio [aPrR] for symptoms 5.53, 95% confidence interval (CI) [3.63, 8.42]; aPrR for audiometric hearing loss 1.63, 95% CI [1.31, 2.03] compared to age 13–18 years) and among those with a prior history of second-line TB treatment (aPrR for symptoms 1.73, 95% CI [1.66, 1.80]; PrR for audiometric hearing loss 1.33, 95% CI [1.03, 1.73]). Having HIV with cluster of differentiation 4 cell count < 200 cells/mm3 and malnutrition were risk factors but did not reach statistical significance in adjusted analyses. Conclusion: Pre-existing hearing loss is common among patients presenting for DR-TB treatment in South Africa, and those older than the age of 50 years or who had prior second-line TB treatment history were at highest risk.
AB - Purpose: Hearing loss, resulting from aminoglycoside ototoxicity, is common among patients with drug-resistant tuberculosis (DR-TB). Those with pre-existing hearing loss are at particular risk of clinically important hearing loss with aminoglycoside-containing treatment than those with normal hearing at baseline. This study aimed to identify factors associated with pre-existing hearing loss among patients being treated for DR-TB in South Africa. Method: Cross-sectional analysis nested within a cluster-randomized trial data across 10 South African TB hospitals. Patients ≥ 13 years old received clinical and audiological evaluations before DR-TB treatment initiation. Results: Of 936 patients, average age was 35 years. One hundred forty-two (15%) reported pre-existing auditory symptoms. Of 482 patients tested by audiometry, 290 (60%) had pre-existing hearing loss. The prevalence of pre-existing hearing loss was highest among patients ≥ 50 years (adjusted prevalence ratio [aPrR] for symptoms 5.53, 95% confidence interval (CI) [3.63, 8.42]; aPrR for audiometric hearing loss 1.63, 95% CI [1.31, 2.03] compared to age 13–18 years) and among those with a prior history of second-line TB treatment (aPrR for symptoms 1.73, 95% CI [1.66, 1.80]; PrR for audiometric hearing loss 1.33, 95% CI [1.03, 1.73]). Having HIV with cluster of differentiation 4 cell count < 200 cells/mm3 and malnutrition were risk factors but did not reach statistical significance in adjusted analyses. Conclusion: Pre-existing hearing loss is common among patients presenting for DR-TB treatment in South Africa, and those older than the age of 50 years or who had prior second-line TB treatment history were at highest risk.
UR - http://www.scopus.com/inward/record.url?scp=85086052797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086052797&partnerID=8YFLogxK
U2 - 10.1044/2020_AJA-19-00103
DO - 10.1044/2020_AJA-19-00103
M3 - Article
C2 - 32320639
AN - SCOPUS:85086052797
SN - 1059-0889
VL - 29
SP - 199
EP - 205
JO - American journal of audiology
JF - American journal of audiology
IS - 2
ER -